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Abstract 
Pregenomic RNA (pgRNA) is generated from covalently closed circular DNA 
(cccDNA) and plays important roles in viral genome amplification and replication. 
Hepatic pgRNA and cccDNA expression levels indicate viral persistence and replication 
activity. This study was aimed to measure hepatic pgRNA and cccDNA expression 
levels in various states of hepatitis B virus (HBV) infection. Thirty eight hepatocellular 
carcinoma (HCC) patients, including 14 positive for hepatitis B surface antigen 
(HBsAg) and 24 negative for HBsAg but positive for anti-hepatitis B core antibody 
(anti-HBc) were enrolled in this study. In HBsAg-negative but anti-HBc-negative group, 
HBV-DNA was detected in 20 of 24 (83%) noncancerous liver tissues for at least two 
genomic regions based on polymerase chain reaction (PCR) analysis. PgRNA and 
cccDNA expression levels in occult HBV-infected patients were significantly lower 
than those in HBsAg-positive patients (P < 0.001). PgRNA and cccDNA in cancerous 
tissues were also detected without significant difference of those in noncancerous 
tissues. In conclusion, cccDNA and pgRNA are detected and represented HBV 
replication not only in noncancerous but also in cancerous liver tissues. In addition, the 
replication is shown in not only patients with HBsAg-positive but also occult HBV 
infected patients, suggesting the contribution to HCC development. 
 
(Electronic word count: 198) 
Key words: HBV, cccDNA, pgRNA, replication, occult 
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1. Introduction 
Hepatitis B virus (HBV) infection remains a major health problem, even though 
methods for preventing vertical transmission and treatment guidelines have been 
introduced. Approximately, 2 billion people worldwide are infected with HBV. Three 
hundred fifty million of them have chronic infection. HBV is particularly endemic in 
sub-Saharan Africa, the Pacific, and Asia [1]. It frequently causes chronic hepatitis, 
which subsequently, progress to liver cirrhosis and hepatocellular carcinoma (HCC). 
HBV is responsible for most of the worldwide attributable risk of liver cirrhosis and 
HCC. The risk is even higher in endemic regions [2]. 
HBV is an incomplete double-stranded circular DNA virus, with a DNA length of 
approximately 3,200 bp. After HBV infects the liver cells, the relaxed-circular DNA is 
transferred into the nucleus and is repaired to covalently closed-circular DNA 
(cccDNA) by DNA polymerase. The cccDNA plays a key role in the life cycle of the 
virus. It acts as a template for the generation of mRNAs, including pregenomic RNA 
(pgRNA) [3-5]. The transcription of cccDNA generates four kinds of mRNA: PreC/C 
(3.5 kb), PreS1 (2.4 kb), S (2.1 kb), and X (0.7 kb). The transcription of cccDNA is a 
critical step for viral genomic amplification and replication. PgRNA is also generated 
during the transcription from cccDNA and works as a template of viral genomic DNA.  
The cccDNA is detected in various phases of chronic hepatitis, and its levels 
reflect viral replication in the infected cells. HBV-DNA is sometimes detected in 
patients negative for hepatitis B surface antigen (HBsAg) but positive for anti-hepatitis 
B core antibody (anti-HBc) and or anti-hepatitis B surface antibody (anti-HBs), which is 
often called occult HBV infection [4]. Recent studies revealed that cccDNA was 
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expressed in HCC without HBs antigen [5]. However, it is still debated whether HBV-
DNA is responsible for the development of HCC in patients with occult HBV infection. 
In this study, we measured the levels of cccDNA and pgRNA in cancerous and 
contiguous noncancerous liver tissues of HCC patients with overt and occult HBV 
infection to examine the viral existence and replication. We also determined the 
nucleotide variations and amino acid mutations in patients with occult HBV infection. 
 
2. Materials and Methods 
2.1. Patients. Cancerous and contiguous noncancerous liver tissues were obtained from 
38 HCC patients (mean ± SD, 63.37 ± 12.01 years; male-female ratio, 34/4) who 
underwent surgical resection at Kobe University Hospital, Japan, between April 2010 
and December 2011. HBsAg-positive carriers (n = 14) and HBsAg-negative/ HBcAb-
positive patients (n = 24) were enrolled in this study. Hepatitis C virus (HCV) infected 
patients who were detected by anti-HCV positivity were excluded. Tissue samples were 
rapidly frozen in liquid nitrogen and stored at –80 °C after resection.  
 The demographic and clinical data, including age, sex, the body mass index 
(BMI), results of standard test for HBV-related HCC, and stage of the disease were 
collected from medical record after institutional review board approval was obtained.  
Written informed consent was obtained from each patient before all the 
procedures in this study were done. This study was reviewed and approved by the 
Ethics Committee at Kobe University. 
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2.2. Detection of HBV-DNA, cccDNA, and pgRNA in tissue samples. Total DNA and 
RNA from cancerous and contiguous noncancerous tissues were extracted from about 
20 mg of liver tissues using a QIAamp DNA Mini Kit (QIAGEN) and Isogen 
(Nippongene, Tokyo, Japan). The DNA and RNA concentrations were measured 
spectrophotometrically. The cDNA was synthesized from five µg of total RNA using 
the Oligo (dT) 15 primer (Promega, Madison, WI) and M-MLV Reverse Transcriptase 
(Invitrogen, Carlsbad, CA) according to the manufacturers’ instructions. 
To detect intrahepatic HBV-DNA, a nested polymerase chain reaction (PCR) was 
carried out using the specific primers for amplifying S, precore-core, polymerase, and X 
region. The primers used are listed in Table 1. The first and second round PCRs were 
performed under the same condition described previously [5]. Appropriate controls 
were included in each PCR. The PCR products were resolved on 2% agarose gels and 
visualized under ultraviolet illumination with ethidium bromide staining. Patients whose 
were negative serologically for HBsAg but positive for intrahepatic HBV-DNA at least 
in two regions of HBV genome based on PCR assays, were defined as having occult 
infections. 
We further performed quantitative real-time PCR using an Applied Biosystems 
7500 RT-PCR System (Applied Biosystems, Foster City, CA). Briefly, 2 µl of HBV-
cccDNA or pgRNA was amplified using TaqMan Gene Expression master mix 
(Applied Biosystems), primers for cccDNA (CCC and BC1) or pgRNA (PGP and BC1), 
and FRET hybridization probes (hbvLC and hbvFL) as listed in Table 1. The 
amplification was performed under conditions described previously [6]. 
6 
 
To avoid cross-contamination between samples, standard precautions were used 
for all procedures. Reagents, samples, and amplified products were stored in separate 
areas. 
 
2.3. Determination of HBV genotypes and subgenotypes. HBV genotypes and 
subgenotypes were determined by phylogenetic analysis based on the S region. Part of S 
region was amplified in PCR using HB2F and HB2R primer (Table 1) with condition 
described previously [7]. The amplified fragments were purified using ExoSAP-IT 
(USB, Cleveland, OH) and directly sequenced using BigDye Terminator v3.1. Cycle 
Sequencing Kit (Applied Biosystems, Foster City, CA). The sequencing was performed 
in an ABI PRISM 3100-Avant genetic analyzer (Applied Biosystems, Foster City, CA). 
The sequences were edited manually and subsequently aligned using Clustal X version 
2.0.12 software (http://www.clustal.org/). A phylogenetic tree was constructed by the 
neighbor-joining method using the Molecular Evolutionary Genetic Analysis (MEGA) 
version 4.0.2 software (http://megasoftware.net/) [8]. To show the reliability of this 
analysis, bootstrap resampling and reconstruction were performed 1,000 times [9].  
 
2.4. Detection of amino acid substitutions in the “a” determinant region and mutations 
in the core promoter and precore region. Some amino acid substitutions in the “a” 
determinant region are thought to result in detectable HBV-DNA in HBsAg-negative 
patients. Therefore, the sequences within this region were aligned and analysed to 
identify amino acid substitutions among HBV strains obtained from patients positive for 
HBV-DNA. We used the previously described primer pairs as shown in Table 1 [7] to 
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amplify the “a” determinant region. Core promoter and precore region were also 
amplified using primers and condition described previously (Table 1) [7].  
Those amplified fragments were directly sequenced, and the obtained 
sequences from each region were aligned with reference sequences retrieved from 
GenBank databases to identify the substitutions or mutations.  
 
2.5. Statistical analyses. Statistical analyses were performed using IBM SPSS Statistics 
version 21.0 (IBM, Armonk, NY). The categorical variables were analyzed using the χ2 
test or Fisher’s exact test, whereas continuous variables were analyzed using 
independent t-tests or the Mann–Whitney test. Differences were considered statistically 
significant at P < 0.05. 
 
3. Results 
3.1. Clinical characteristics of the patients. The clinical characteristics of HBsAg-
negative/HBcAb-positive patients were compared with those of HBsAg-positive 
carriers (Table 2). The HBsAg-positive carriers were significantly younger than 
HBsAg-negative/HBcAb-positive patients (55.7 ± 12.0 vs. 68.7 ± 9.3 years; P = 0.002). 
The complication of diabetes mellitus is significantly higher in HBsAg-
negative/HBcAb-positive patients. It was indicated by higher level of HbA1c in this 
group (5.96 ± 0.87 vs. 5.04 ± 0.33; P < 0.001). Ten of them (42%) were treated by oral 
medication and or insulin injection therapy for diabetes. In addition, four patients had 
massive alcohol consumptions and had been diagnosed as alcoholic cirrhosis. The 
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average body-mass-index (BMI) in HBsAg-negative/HBcAb-positive patients tended to 
be high compared with those in HBsAg-positive carriers (23.1 ± 3.4 vs. 20.5 ± 3.7; P = 
0.079) although not significant statistically. Four HBsAg-positive patients were treated 
by nucleotide analogue more than one year and HBV-DNA were undetectable in their 
sera. A significantly greater proportion of HBsAg-positive carriers had an HBV viral 
load of >4 log copies/ml as compared with HBsAg-negative/HBcAb-positive patients 
(42.9% vs. 0%; P = 0.012). Thirty two HBV strains could be genotype. Almost all 
(96.9%) patients were infected by genotype C2. Only one patient (3.1%) was infected 
by genotype B1 (Table 2 and Figure 2). 
 
3.2. Detection of HBV-DNA, cccDNA, and pgRNA in the tissue. Based on the nested 
PCR analysis, HBV-DNA was detected in all cancerous and noncancerous tissues of 
HBsAg-positive carriers. On the other hand, at least two HBV genomic regions were 
detected in 20 of 24 (83%) noncancerous tissues from HBsAg-negative/HBcAb-positive 
patients (P = 0.003). Those patients were classified as having occult HBV infection. 
The S (71% vs. 38%, P = 0.02) and X (88% vs. 50%, P = 0.005) regions were detected 
more frequent in noncancerous tissues than in cancerous tissues (Table 3). Twenty 
patients with occult HBV infection and were compared with 14 HBsAg-positive carriers. 
The mean pgRNA and cccDNA expression levels in noncancerous tissues were 
significantly lower in occult HBV-infected patients (5.72 ± 1.22 log copies/µg of 
extracted RNA and 7.52 ± 1.48 log copies/µg of extracted DNA, respectively) than in 
HBsAg-positive carriers (7.55 ± 1.50 log copies/µg of extracted RNA and 10.37 ± 1.15 
log copies/µg of extracted DNA, respectively; both, P < 0.001). In addition, pgRNA and 
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cccDNA expression levels in cancerous tissues were lower in occult HBV-infected 
patients (6.11 ± 1.08 log copies/µg of extracted RNA and 7.84 ± 1.91 log copies/µg of 
extracted DNA, respectively) than in HBsAg-positive patients (8.10 ± 1.77 log 
copies/µg of extracted RNA and 10.02 ± 4.28 log copies/µg of extracted DNA, 
respectively; P = 0.004 and P = 0.201, respectively; Figure 1). The pgRNA and 
cccDNA in HBsAg-positive patients were also compared in relation with nucleotide 
analogue therapy. However, no significant difference was detected between under 
treated patients and naïve patients (pgRNA, 7.58 ± 1.48 vs. 7.45 ± 1.62 log copies/µg of 
extracted RNA; cccDNA, 10.13 ± 0.98 vs. 10.15 ± 1.34 log copies/µg of extracted DNA, 
respectively). The ratio of pgRNA/ cccDNA in noncancerous tissues was also examined, 
but no difference was detected between HBsAg-positive patients and occult HBV-
infected patients (0.75 ± 0.18 vs. 0.85 ± 0.19, respectively).  
 
3.3. Amino acid subtitutions in the “a” determinant region and mutations in the core 
promoter and precore region. Table 4 shows the distribution of amino acid substitutions 
in the “a” determinant region in HBsAg-positive patients and occult HBV-infected 
patients. Two specific substitutions (I126T and I126V) were detected in the occult HBV 
infection group. However, all of the occult infected patients had the viral loads less than 
4 log copies/ml. Substitutions in I126T and T131P were also detected in HBsAg-
positive patients.  
The A1762T/G1764A, T1846A, C1858, and G1896A mutations were detected 
in HBsAg-positive carriers and in occult HBV-infected patients, without significant 
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differences in their prevalence rates. However, the T1753C mutation was only found in 
HBsAg-positive carriers (29%) and it was statistically significant (P = 0.033; Table 5).  
 
4. Discussion 
HBV is a major cause of HCC in most Asian countries. Chronic HCV infection is the 
leading cause and HBV infection is the second most common cause of HCC in Japan 
[10]. However, approximately 10% of HCC patients were serologically negative for 
HBsAg and HCV-Ab [11]. Chronic forms of hepatitis, particularly alcoholic hepatitis, 
steatohepatitis, and autoimmune hepatitis, may induce HCC in the absence of hepatitis 
viral infection. The number of cases of HCC without hepatitis viral infection has 
increased in recent years because of the introduction of vaccination programmes aimed 
at preventing vertical transmission of HBV and screening systems to prevent HCV 
infection from transfusion and transmission [12]. 
Occult HBV infection is diagnosed when serum is negative for HBsAg but serum 
or liver is positive for HBV-DNA, regardless of anti-HBc status [13]. Several studies 
have assessed HBV-DNA status in HBsAg-negative HCC patients [14-15]. However, it 
is still controversial whether occult HBV infection is associated with liver damage. In 
particular, although it was reported that occult HBV infection did not progress to severe 
liver disease [16], other studies showed that occult HBV infection caused liver disease 
progression in patients with chronic HCV infection [17]. 
Earlier studies suggested that individuals could recover from self-limited acute 
hepatitis because of the role of cytotoxic or memory T cells. However, these patients 
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might carry the HBV genome for a long time without showing clinical signs of hepatic 
injury [18]. Furthermore, histopathological examination of such patients showed mild 
necroinflammation after decades of recovery [19]. In the immunocompetent state, occult 
HBV is not destructive, but progressive liver dysfunction may occur if other deleterious 
factors are present [20]. In this study, the HBsAg-negative/HBcAb-positive patients 
were significantly older than the HBsAg-positive carriers, suggesting that the 
hepatocarcinogenesis between these two groups were different. 
The association of occult HBV infection with HCC has been extensively reviewed 
[21]. It was also reported that cryptic HBV infection had a pro-oncogenic role in 
chronic HCV carriers and in cryptogenic liver diseases [15]. In animal studies, 
woodchucks and ground squirrels infected with woodchuck or ground-squirrel hepatitis 
virus, liver cancer progression was apparent, even after elimination of these viruses [22]. 
A previous study showed that occult HBV was strongly associated with liver cancer, 
independently of age, sex, cirrhosis, and contemporary HCV infection. Aside from 
indirect oncogenic mechanisms (e.g., mild necroinflammation), direct oncogenic 
mechanisms, including viral integration into the host genome and maintenance of 
transcriptional activity, allow the production of potential pro-oncogenic factors, such as 
X protein, which may contribute to the development of cirrhosis and liver cancer [15]. 
In the present study, cccDNA and pgRNA in cancerous tissues were higher than 
those in noncancerous tissues, and it was supported that previous data [5]. However, 
several reports showed that cccDNA in cancerous tissues were lower than those in 
noncancerous tissues [23]. The controversial result might be dependent on the 
difference of the necroinflammation and liver fibrosis [24]. It was also reported that 
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cccDNA in the liver was correlated with serum HBV-DNA viral load and decreased 
during antiviral therapy [25]. In the present study, four HBsAg-positive patients were 
treated by nucleotide analogue therapy more than one year. However, cccDNA was no 
different regardless of therapy. It might be partly caused by sample number and 
therapeutic duration. 
This study revealed that intrahepatic cccDNA and pgRNA levels in cancerous and 
noncancerous tissues were low in occult HBV-infected patients, and were lower than 
those in HBsAg-positive carriers. These results suggest that transcriptional activity was 
low in occult HBV-infected HCC patients. Even though transcriptional activity and 
replication were lower in HCC patients with occult HBV infection, it might still be 
sufficient to induce HCC [5]. 
Other studies have detected cccDNA and pgRNA in cancerous and noncancerous 
tissues in patients with occult HBV infection [5, 15]. HBV cccDNA is formed from 
relaxed circular-DNA and enters the nuclei of the host’s cells. This stable non-
integrated mini chromosome is used as a template for the transcription of viral mRNAs 
and pgRNA. In turn, viral mRNA is used to generate viral proteins and replication 
factors. The pgRNA is then encapsidated and reverse-transcribed into HBV DNA. 
Animal experiments revealed that 1–50 cccDNA molecules gather in the nucleus, but 
the viral and host factors that regulate cccDNA are still poorly defined [26].  
Some studies of duck hepatitis B virus revealed a negative feedback mechanism 
by which large surface protein suppresses cccDNA production [27]. In the present study, 
the S and X regions were detected in significantly more noncancerous tissues than in 
cancerous tissues. A previous study reported that a decrease in HBsAg expression in the 
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cancer may contribute to an increase in intrahepatic HBV DNA in the form of cccDNA 
in cancerous tissues, suggesting that viral replication is minimal within cancer cells and 
that the majority of intrahepatic HBV DNA is in the form of cccDNA [15]. In the 
present study, the expression levels of cccDNA and pgRNA in HCC patients with 
occult HBV infection were similar or slightly lower in noncancerous tissues than in 
cancerous tissues, although more studies are needed to confirm these findings. However, 
the present results suggest that HBV persisted and was continuously replicated in 
cancerous and noncancerous cells. 
Mutations in the S gene may alter HBsAg antigenicity and anti-HBs production. It 
was reported that a single amino acid mutation in the “a” determinant region (amino 
acids 124–147) of HBsAg could lead to a change in the immunologic epitope [28], and 
mutations or deletion in the S gene disrupted HBsAg production [29]. In the present 
study, two specific substitutions (I126T and I126V) were detected in occult HBV-
infected patients. However, the HBV-DNA titre was <4 log copies/ml in all of the 
occult HBV-infected patients. Therefore, it is still unclear whether these substitutions 
are related to viral replication. 
In conclusion, the present study confirmed that HBV persisted and was 
continuously replicated in cancerous and noncancerous tissues. In addition, cccDNA 
and pgRNA levels were thought to represent HBV replication in the liver, and might 
contribute to the development of HCC in HBsAg carriers and occult HBV-infected 
patients. 
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Figure legend 
 
FIGURE 1: Quantitative analysis of pgRNA (a,c) and cccDNA (b,d) in noncancerous 
and cancerous liver tissues. The pgRNA and cccDNA expression levels were 
significantly higher in HBsAg-positive patients than in occult HBV-infected patients. 
 
FIGURE 2: Phylogenetic tree analysis of the S gene sequences of strains isolated in this 
study. The HBV strains from different genotypes (A to H) are obtained from GenBank. 
The GenBank HBV sequences are indicated with their accession number followed by 
genotypes. The sequences determined in this study are indicated by isolate number, 
starting with HBSAG or OBI, and are labelled with black circles or triangles, for 
HBsAg-positive patients or patients with occult HBV infection respectively.  
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TABLE 1: Sequences and positions of primers and probes used in this study 
Primer and probe Region Position Polarity Sequence (5’ to 3’) Reference 
Occult case determination 
HBV 1 
HBV 2 
HBV 17 
HBV 4 
HBV 5 
HBV 6 
HBV 7 
HBV 8 
Pol 1 S 
Pol 1 AS 
Pol 2 S 
Pol 2 AS 
X 1 S 
HBV 19 
HBV 15 
HBV 21 
 
Genotyping and amplification 
of “a” determinant region 
HB2F 
HB2R 
 
Amplification of core 
promoter and precore regions 
HB7F 
HB7R 
 
cccDNA and pgRNA 
quantification 
CCC 
PGP 
BC1 
hbvLC 
hbvFL 
 
PreS-S 
PreS-S 
PreS-S 
PreS-S 
Precore-core 
Precore-core 
Precore-core 
Precore-core 
Polymerase 
Polymerase 
Polymerase 
Polymerase 
X 
X 
X 
X 
 
 
 
S 
S 
 
 
 
C 
C 
 
 
 
X 
X/C 
C 
C 
C 
 
2815–2834 
690–671 
3037-3057 
459–440 
2021–2040 
2464–2448 
2048–2066 
2385–2366 
2412-2430 
256-237 
2452-2476 
2838-2814 
1100-1121 
1550–1529 
1380–1400 
1518–1497 
 
 
 
414-433 
989-970 
 
 
 
1611-1630 
2072-2048 
 
 
 
1555-1573 
1826-1843 
1974-1955 
1874-1848 
1897-1876 
 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense 
Antisense 
Sense  
Antisense 
Sense 
Antisense 
Sense 
Antisense 
 
 
 
Sense 
Antisense 
 
 
 
Sense 
Antisense 
 
 
 
Sense 
Sense 
Antisense 
Antisense 
Antisense 
 
GGTCACCATATTCTTGGGAA 
AATGGCACTAGTAAACTGAG 
AATCCAGATTGGGACTTCAA 
CCTTGATAGTCCAGAAGAAC 
GCCTTAGAGTCTCCTGAGCA 
GTCCAAGGAATACTAAC 
CCTCACCATACTGCACTCA 
GAGGGAGTTCTTCTTCTAGG 
CGCGTCGCAGAAGATCTCA 
CGAGTCTAGACTCTGTGGTA 
GTATYCCTTGGACTCATAAGGTGGG 
CTTGTTCCCAAGAATATGGTGACCC 
CGCCAACTTACAAGGCCTTTCT 
CGTTCACGGTGGTCTCCAT 
GCTAGGCTGTGCTGCCAACTG 
GGTCGGTCGGAACGGCAGACGG 
 
 
 
TGCTGCTATGCCTCATCTTC 
CATACTTTCCAATCAATAGG 
 
 
 
GAGACCACCGTGAACGCCCA 
CCTGAGTGCTGTATGGTGAGG 
 
 
 
GTGCCTTCTCATCTGCCGG 
CACCTCTGCCTAATCATC 
GGAAAGAAGTCAGAAGGCAA 
GGAGGCTTGAACAGTAGGACATGAA
C 
CYAAAGCCACCCAAGGCACAGC 
 
[15] 
[15] 
[15] 
[15] 
[15] 
[15] 
[15] 
[15] 
[5] 
[5] 
[5] 
[5] 
[5] 
[15] 
[15] 
[15] 
 
 
 
[7] 
[7] 
 
 
 
[7] 
[7] 
 
 
 
[6] 
[6] 
[6] 
[6] 
[6] 
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TABLE 2: Clinical characteristics of patients. 
 HBsAg-positive carriers (n = 14) 
HBsAg–/HBcAb+ 
patients (n = 24) P-value 
Male/female 13/1 21/3 NS 
Age (years) 55.7 ± 12.0 68.7 ± 9.3 0.002 
BMI 20.5 ± 3.7 23.1 ± 3.4 NS 
Prevalence of BMI >22 3/14 (21%) 14/24 (58%) 0.03* 
Platelet count (/mm3) 18.1 ± 4.0 19.3 ± 8.4 NS 
Albumin (g/dl) 4.2 ± 0.6 3.9 ± 0.6 NS 
AST (IU/l) 30.3 ± 5.9 74.0 ± 59.6 NS 
HbA1c 5.04 ± 0.33 5.96 ± 0.87 <0.001 
ICG-R 15 (%) 9.54 ± 2.76 11.15 ± 5.22 NS 
Child-Pugh (A/B/C) 13/1/0 18/3/0 NS 
HBV-DNA >4 log copies/ml 6 (42.9) 0 (0.0) 0.012 
Genotype B/C 1/13 0/17 NS 
AFP >200 (ng/ml) 7 (50%) 8 (33.3%) NS 
PIVKA-II >400 (mAU/ml) 9 (64.3%) 14 (58.3%) NS 
Stage I/II/III/IV 1/4/2/3 1/6/2/9 NS 
AST, aspartate aminotransferase; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or 
antagonist II; NS, not significant. 
*Mann-Whitney’s U test 
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TABLE 3: Detection of HBV-DNA in 24 HCC patients with HBsAg-negative and 
HBcAb-positive patients. 
 Cancerous tissue Noncancerous tissue P-value 
S region 9 (38%) 17 (71%) 0.020 
Precore-core region 4 (17%) 4 (17%) NS 
Polymerase region 14 (58%) 10 (42%) NS 
X region 12 (50%) 21 (88%) 0.005 
Positive in ≥2 regions 10 (42%) 20 (83%) 0.003 
NS, not significant. 
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TABLE 4: The alignment of ’a’ determinant amino acid sequences. 
Sample number or GenBank accession 
numbers Genotype 
Amino acids alignment (124-147) 
in the “a” determinant region 
Consensus sequences 
D23684 
D23678 
Occult HBV infection 
OBI-1 
OBI-2 
OBI-4 
OBI-5 
OBI-6 
OBI-7 
OBI-8 
OBI-9 
OBI-10 
OBI-11 
OBI-12 
OBI-13 
OBI-14 
OBI-15 
OBI-16 
OBI-17 
OBI-18 
HBsAg-positive patients 
HBSAG-1 
HBSAG-2 
HBSAG-3 
HBSAG-4 
HBSAG-5 
HBSAG-6 
HBSAG-7 
HBSAG-8 
HBSAG-9 
HBSAG-10 
HBSAG-11 
HBSAG-12 
HBSAG-13 
HBSAG-14 
 
C2 
B1 
 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
C2 
B1 
C2 
C2 
 
CTIPAQGTSMFPSCCCTKPSDGNC 
-------------------T---- 
 
------------------------ 
--V--------------------- 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
--T--------------------- 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
 
-------P---------------- 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
--T--------------------- 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
------------------------ 
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TABLE 5: Mutations in the core promoter and precore regions in patients divided by 
serological status. 
 HBsAg-positive carriers (n = 14) 
Occult HBV-infected 
patients (n = 9) P-value 
T1753C 4 (29%) 0 (0%) 0.033 
A1762T/G1764A 11 (79%) 5 (56%) NS 
T1846A 3 (21%) 3(33%) NS 
G1896A 8 (57%) 4 (44%) NS 
NS, not significant. 
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